MRES:
M2Bio Sciences Unveils an Exciting Line of Purple, White, and Green
Teas from Kenya, Offering Extraordinary Health and Medicinal
Benefits
CAPE TOWN,
SOUTH AFRICA -- July 14, 2023 -- InvestorsHub NewsWire -- Institute
of Biomedical Research Corp. (OTC PINK: MRES) ("Institute of Biomedical
Research" or the "Company"), a nutraceutical biotechnology company
focused on alternative plant-based cannabinoids, medical psilocybin
and mental health therapeutic research powered by artificial
intelligence, and evidence-based sustainable products and
solutions, is pleased to share the following update:
M2Bio
Sciences is thrilled to announce the forthcoming launch of a
captivating line of Purple, White, and Green teas, sourced from the
scenic tea gardens of Kenya. This meticulously crafted collection
of teas not only provides an exquisite sensory experience but also
delivers exceptional health and medicinal benefits.
Kenya,
renowned for its picturesque tea plantations and rich tea heritage,
is the birthplace of these exceptional teas. M2Bio Sciences has
collaborated with esteemed tea experts in Kenya to bring the
essence of this remarkable region to tea enthusiasts and
health-conscious individuals worldwide.
Purple Tea,
grown exclusively in the pristine highlands of Kenya, is
distinguished by its stunning violet leaves. This unique variety is
packed with anthocyanins, potent antioxidants known for their
anti-inflammatory properties. Purple Tea offers remarkable health
benefits, such as supporting cardiovascular health, boosting the
immune system, and promoting healthy aging. Its distinct taste
profile, a harmonious blend of fruity and earthy notes, elevates
the tea-drinking experience to new heights.
White Tea,
carefully handpicked from tender tea leaves and buds, is prized for
its delicate and nuanced flavors. With minimal processing, White
Tea retains a higher concentration of antioxidants compared to
other tea varieties. Regular consumption of this exquisite tea can
aid in detoxification, promote healthy skin, and provide anti-aging
benefits. The mild and soothing character of White Tea creates a
truly calming and rejuvenating experience.
Green Tea,
beloved for its vibrant green hue and refreshing taste, has been
celebrated for centuries for its multitude of health benefits.
Bursting with polyphenols and catechins, Green Tea offers powerful
antioxidants that support heart health, enhance cognitive function,
and aid in weight management. Its invigorating flavor and
energizing properties make it a perfect choice for those seeking a
healthful boost throughout the day.
"We are
delighted to introduce our exceptional line of Purple, White, and
Green teas from Kenya," stated
Jeff Robinson, CEO of M2Bio Sciences. "Our
Purple tea strain has about 40 times more antioxidants compared to
a traditional green tea so we definitely tick the box for health.
In terms of addressable market, green tea sales for 2022 were
estimated to be $22 Billion globally. We plan to take a good chunk
of that! Robinson added: "These teas embody our commitment to
providing products that promote holistic well-being. Through our
partnership with the esteemed tea experts of Kenya and our team of
researchers in the M2Bio Phytomedicine Labs at the University of
Pretoria, we are able to offer tea enthusiasts worldwide an
unparalleled combination of extraordinary taste and outstanding
health benefits.
In a
display of dedication to sustainable sourcing practices, CEO Jeff
Robinson will embark on a journey to Kenya from July 24th to July
31st. During his visit, Mr. Robinson will engage with local tea
farmers, explore initiatives promoting sustainability, and
strengthen the partnership between M2Bio Sciences and the Kenyan
tea community. This trip underscores the company's commitment to
ethical practices, supporting local economies, and ensuring the
highest quality of its tea offerings.
The
captivating Purple, White, and Green teas from Kenya will be
available for purchase online and through select retailers starting
in Q1 2024. M2Bio Sciences invites tea enthusiasts and
health-conscious individuals to embark on a transformative
tea-drinking experience, harnessing the exceptional flavors and
medicinal benefits of these extraordinary teas.
About Institute of
Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research
Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, that develops
and commercializes a range of CBD and mushrooms-based products
under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as
artificial intelligence powered nutrition products and solutions
under the M2Biome brand. In addition, our research and clinical
trials with psilocybin are aimed at new therapies that will help
patients who suffer from alcohol addiction, mental illness, and
cardiovascular diseases. Our mission is to advance botanical-based
medicine to the forefront by deploying best-practice science and
medicine, clinical research, and emerging technologies such as
artificial intelligence. The Company is traded on the
Over-the-Counter Bulletin Board of NASDAQ under the trading symbol
"MRES".
Publicly traded Company (OTC
Pink: MRES)
www.m2bio.co
jeff@m2bio.co
+27 72 333 2148
Find M2Bio™ on
social media
Facebook:
M2Bio
Instagram:
M2bio.Sciences
LinkedIn:
M2Bio
Twitter:
@M2bio
Forward-Looking
Statements
Safe Harbour
Statement - In addition to historical information, this press
release may contain statements that constitute forward-looking
statements within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this press release include the intent,
belief, or expectations of the Company and members of its
management team with respect to the Company's future business
operations and the assumptions upon which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future
performance, involve risks and uncertainties and that actual
results may differ materially from those contemplated by such
forward-looking statements. Factors that could cause these
differences to include, but are not limited to, failure to complete
anticipated sales under negotiations, lack of revenue growth,
client discontinuances, failure to realize improvements in
performance, efficiency, and profitability, and adverse
developments with respect to litigation or increased litigation
costs, the operation or performance of the Company's business units
or the market price of its common stock. Additional factors that
could cause actual results to differ materially from those
contemplated within this press release can also be found on the
Company's website. The Company disclaims any responsibility to
update any forward-looking statements. mres